Uncategorized
Lucentis improves myopic choroidal neovascularization
ZURICH (Reuters) - Switzerland's Novartis said on Wednesday new data for Lucentis demonstrated its
benefits in treating myopic choroidal neovascularization secondary to pathological myopia, which Novartis will seek
approval for.